May 15, 2025 07:30AM
May 7, 2025 06:30AM
May 6, 2025 07:00AM
Apr 29, 2025 06:30AM
Apr 10, 2025 07:30AM
Apr 10, 2025 07:30AM
Mar 31, 2025 07:00AM BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
Nov 11, 2024 06:00AM
Oct 28, 2024 06:00AM
Oct 7, 2024 07:00AM
Sep 24, 2024 06:00AM
Aug 14, 2024 07:05AM
Jun 26, 2024 08:02AM
Jun 26, 2024 08:00AM BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial
May 20, 2024 06:00AM
May 14, 2024 04:30PM
Apr 17, 2024 05:42AM
Apr 16, 2024 06:30PM
Apr 10, 2024 06:01AM
Apr 10, 2024 06:00AM
Apr 9, 2024 06:01AM Brainstorm Cell Therapeutics (BCLI) Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
Apr 9, 2024 06:00AM
Apr 8, 2024 06:00AM
Apr 1, 2024 08:05AM
Feb 27, 2024 06:32AM
Feb 27, 2024 06:30AM
Feb 23, 2024 06:00AM
Feb 23, 2024 06:00AM BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
Feb 13, 2024 06:30AM
Dec 26, 2023 07:30AM
Dec 26, 2023 07:30AM
Dec 20, 2023 09:01AM
Dec 20, 2023 09:00AM
Dec 7, 2023 08:40AM
Dec 7, 2023 08:40AM BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS
Sep 28, 2023 05:20AM
Sep 27, 2023 10:48PM
Sep 27, 2023 07:01AM
Sep 27, 2023 07:00AM
Aug 14, 2023 07:05AM
Jul 12, 2023 07:02AM
Jul 12, 2023 07:00AM BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer
Jun 6, 2023 06:02AM
Jun 6, 2023 06:00AM
May 15, 2023 07:05AM
Mar 30, 2023 07:05AM

15,418 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All